Get research updatesPublic study records, presented in a clearer and more patient-friendly format for mental health research discovery.
A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS Methylphenidate (54 and 72 mg/Day) in Adults With Attention Deficit/Hyperactivity Disorder
This study has finished and is no longer accepting participants.
In FranceResearchers compared Paliperidone ER, placebo and Olanzapine to find out how the approaches affected how long people remain free of a new mood episode in people with bipolarity type I.
This study has finished and is no longer accepting participants.
In FranceA Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Adaptive Dose-Finding Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
This study has finished and is no longer accepting participants.
In FranceThis study evaluated the safety and effectiveness of Esketamine for people with depression.
This study has finished and is no longer accepting participants.
In FranceThis study evaluated the safety and effectiveness of Esketamine for people with depression.
This study has finished and is no longer accepting participants.
In FranceThis study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In FranceResearchers compared BI 1358894 and placebo, tracking side effects to assess safety in people with borderline personality difficulties.
This study has finished and is no longer accepting participants.
In FranceThis study evaluated the safety of TV-46000 for people with schizophrenia.
This study has finished and is no longer accepting participants.
In FranceResearchers are studying Iclepertin, tracking side effects to assess long-term safety in people with schizophrenia.
This study ended early.
In FranceResearchers compared BI 1358894, placebo and Quetiapine to find out how the approaches affected depression symptoms in people with depression.
This study has finished and is no longer accepting participants.
In France
Cross-sectional Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
This study has finished and is no longer accepting participants.
In FranceA Comparative, Randomized, Open-Label, Multicenter Study on the Efficacy and Safety of Switch Treatment With Aripiprazole in Schizophrenic Out-patients Who Are Experiencing Insufficient Efficacy With Risperidone and/or Safety and Tolerability Issues, While on Risperidone
This study has finished and is no longer accepting participants.
In FranceWe gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.